HUM
Earnings call · Mar 2025 (Q1 FY25)

HUMANA Q1 FY25 earnings call HUM

Apr 30, 2025 Source

Executive summary

Humana Q1 FY25 — Solid Start, Reaffirmed Guidance, and Strategic Focus

Humana reported a solid Q1 FY25, reaffirming its full-year adjusted EPS guidance despite some timing-related outperformance. The company is focused on operational execution, particularly in Stars performance, G&A efficiency, and the growth of its CenterWell and Medicaid segments. While external challenges like Stars litigation and IRA dynamics persist, management emphasizes that underlying business fundamentals are developing as expected, with a long-term focus on unlocking earnings potential.

Highlights

5

  • Reaffirmed full-year adjusted EPS guidance of approximately $16.25, reflecting a solid start to the year.

  • CenterWell segment outperformed expectations, contributing approximately one-third of the quarterly beat, driven by PCO and Pharmacy.

  • Medicaid segment showed strong growth of approximately 100,000 members year-to-date, on track for 175,000 to 250,000 expected growth for the year.

  • Secured an intent to award notice from Illinois for a new dual eligible special needs program, opening access to 450,000 duals.

  • G&A costs were slightly better than expectations due to timing and progress in cost management efforts, including increased AI use in contact centers.

Concerns

5

  • GAAP EPS revised lower by approximately $1.20 or 8% due to a put call valuation adjustment for CenterWell primary care centers, though management states no structural impairment.

  • Some outperformance in Q1 was timing-related, with expenses expected to shift to Q2 and Q3, particularly for Stars investments.

  • Stars litigation timing remains uncertain, impacting the path to the 3% MA margin target.

  • IRA changes are influencing consumer and manufacturer behavior, requiring continued monitoring.

  • Dock 6 impact is anticipated late in Q3 or Q4, potentially putting pressure on year-end earnings, though contemplated in guidance.

Guidance & targets

CategoryTargetConfidence
Adjusted EPS
approximately $16.25
high materiality
High
Insurance segment benefit ratio
90.1% to 90.5%
high materiality
High
Medicaid membership growth
175,000 to 250,000
medium materiality
High
MA margin target
3%
high materiality
Medium
MA margin target
normalized margins in '27
high materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Insurance
The insurance segment's benefit ratio is expected to be consistent with full-year guidance, though variability occurred in Q1 due to CenterWell outperformance.
Benefit ratio: 90.1% to 90.5% (FY25 guidance)
————
CenterWell Primary Care (PCO)
PCO was ahead of expectations due to higher-than-expected patient growth and some PPD favorability. Maturing clinics are performing consistently with J-curve models.
Patient growth: higher than expected
————
CenterWell Pharmacy
Pharmacy was ahead of expectations due to favorable drug mix, particularly in specialty, and strong agnostic sales.
Specialty sales: strong agnostic salesDrug mix: favorable
————
Medicaid
Medicaid is performing in line with expectations, with strong membership growth and modest margin improvement expected as rates are adjusted to reflect recent trend experience. Expansion into 13 states is underway.
Membership growth YTD: approximately 100,000Expected FY25 membership growth: 175,000 to 250,000Rate visibility: 76% of rates for this year
———modest improvement in margins in '25

Operational metrics

GAAP EPS revision
$1.20 lower by 8%
FY25

GAAP EPS revised lower, but management states no structural impairment to assets.

G&A costs
slightly better than expectations
Q1 FY25

Due to timing of costs and progress in cost management efforts.

Care gap closure
25% year-over-year
annual

Expected improvement through partnerships engaging members without a primary care provider, pairing in-person home visits with virtual health.

Medication adherence campaigns
30% to 50% reduction year-over-year
annual

Reduction in members with late refills through medication adherence campaigns.

CenterWell new centers
30
last year

Fueling growth in primary care.

V28 impact
160
FY25

The V28 impact is playing out as expected, consistent with prior guidance.

Medical cost trend
mid-single-digit growth
FY25

Consistent with expectations and guidance, with higher trends in oncology noted.

Pharmacy growth
low double-digit growth
FY25

Consistent with expectations and guidance.

Part D earnings cadence
60% to 65%
Q1 FY25

Earnings are front-loaded due to IRA changes, with a higher proportion in Q1.

Medicaid states footprint
13
future

Expanding to a footprint of 13 states, with Virginia implementation on track.

Medicaid rate visibility
76%
FY25

High visibility into Medicaid rates for the current year, providing confidence in projections.

Industry KPIs

MetricValueDetails
Utilization trendsmid-single-digit growth %
Stars rate environmentbetter reflects trend environment
Medical loss care ratio90.1% to 90.5% %
Pharmacy scripts specialtylow double-digit growth %
Membership covered lives by lineapproximately 100,000 members
Adjusted EPS EBITDA leverage guidance$16.25 USD
Medical cost trend vs pricing assumptionmid-single-digit growth %

Deals & partnerships

Illinois Intent to award notice for new dual eligible special needs program

Received an intent to award notice from Illinois for their new dual eligible special needs program, a major win for the company.

NovaCare Fulfillment center for weight loss medication

CenterWell Pharmacy has started its work as the fulfillment center for NovaCare's weight loss medication directed to cash pay customers.

3 other companies Fulfillment agreements

Reached fulfillment agreements with three other companies in the past few days.

Risks & headwinds

Stars litigation ruling near-term

timing unknown

Mitigation:Actively working through Stars strategy and mitigation/diversification strategy for bids to reduce concentration on certain contracts.

Timing of expenses Q2 and Q3 FY25

some Q1 outperformance due to timing

Mitigation:Expected shift of certain expenses, particularly Stars investments, to later quarters is already factored into full-year guidance.

IRA changes and consumer behavior ongoing

monitoring trends

Mitigation:Continuously monitoring changes in consumer and manufacturer behavior due to the IRA, with current trends in line with expectations.

Regulatory headwinds ongoing

not new, expected to continue

Mitigation:Focused on controllable factors like medical cost, G&A, and Stars performance to navigate external regulatory environment.

Dock 6 impact late Q3 or Q4 FY25

puts pressure on year-end

Mitigation:Anticipated and contemplated within full-year guidance, reflecting a full-year impact recognized in a short period.

What to watch in Q2 FY25

Stars litigation ruling

next quarter
Current pending
Target ruling announced

Why it matters

The outcome of the Stars litigation will significantly impact the company's Medicare Advantage margin trajectory and bid strategy for future years.

There's nothing new on our litigation related to CMS' 2026 Star ratings. We are still waiting on a ruling.

Q&A highlights

How much of the investments moved out of Q1 into Q2, and was Q1 in line with expectations outside of timing?

Most of the incremental investments flowed through MLR in Q1, but many Stars investments ramped later and will be higher in Q2-Q4. Q1 was largely in line with expectations, with some timing shifts.

“Most of the impact to the -- of the incremental investments flowed through the MLR in the first quarter. It was only about 10 basis points, that was in large part because many of the Stars investments that Jim spoke about ramped later in the quarter, and we would expect them to be higher in the second through the fourth.”

asked by Sarah James · answered by Celeste Mellet

2 min read 6 chapters

Detailed narrative

Q1 Performance and Full-Year Outlook

Humana reported a solid start to 2025, coming in ahead of plan for Q1 and reaffirming its full-year adjusted EPS guidance of approximately $16.25. The underlying fundamentals, including membership, patient growth, revenue, and medical cost trends, are developing as expected. While some Q1 outperformance was timing-related, the company is confident in its ability to manage controllable levers and achieve its annual targets.

Medicare Advantage Strategy and Stars Performance

The company maintains its long-term target of a 3% pre-tax margin for Medicare Advantage, with an expectation to return to normalized margins by 2027, contingent on Stars outcomes. Operational progress on Stars is noted, with efforts to close care gaps by 25% year-over-year and reduce late refills by 30% to 50%. The bid cycle for 2026 is ongoing, with a focus on balancing membership and margins and diversifying contracts to reduce concentration risk, aiming for industry-leading Stars results.

CenterWell Growth and Integration

CenterWell businesses, including Primary Care (PCO), Pharmacy, and Home Health, are experiencing robust patient and membership growth. The segment contributed approximately one-third of the Q1 earnings beat, driven by higher-than-expected patient growth in PCO and favorable specialty drug mix in Pharmacy. The integration between the insurance segment and CenterWell is strong, leading to better health outcomes, reduced ER visits, improved medical adherence, and positive contributions to Stars performance and member retention.

Medicaid Expansion and Performance

Medicaid is emerging as a strong, scaled business, performing in line with expectations for the quarter. The company achieved approximately 100,000 member growth year-to-date, progressing towards its full-year target of 175,000 to 250,000. Key wins include an intent to award notice for Illinois' dual eligible special needs program, opening access to 450,000 duals. Modest margin improvements are anticipated in 2025 as rates are adjusted to reflect recent trend experience, with 76% of rates for the year having visibility.

Medical Cost Trends and Part D Dynamics

Medical cost trends are generally in line with expectations, with mid-single-digit growth on the medical side and low double-digit growth on the pharmacy side. The first quarter saw a heavy flu season, which was anticipated. The impact of IRA changes on Part D is front-loading earnings, with 60% to 65% of Part D earnings expected in Q1. The company has data through April, indicating no trends outside of guidance, and is monitoring consumer and manufacturer behavior changes.

Operational Efficiencies and Capital Allocation

Humana is making good progress in cost management, with G&A costs slightly better than expected. Increased use of AI in contact centers is improving representative interactions and reducing call times. Capital allocation is focused on driving value, with 30 new CenterWell centers added through acquisition and partnership over the last year. The company is also exploring opportunities to increase the efficiency of its balance sheet.

AI-generated summary of the company's earnings call. Not investment advice.